TY - JOUR T1 - Effect of vaccination of pneumococcal infection on the course of chronic obstructive pulmonary disease in combination with diabetes mellitus JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2019.PA4318 VL - 54 IS - suppl 63 SP - PA4318 AU - Elena Blinova AU - Galina Ignatova AU - Vladimir Antonov Y1 - 2019/09/28 UR - http://erj.ersjournals.com/content/54/suppl_63/PA4318.abstract N2 - Objective: to evaluate the effect of conjugated pneumococcal vaccine Prevenar 13 on the course of COPD in combination with type 2 diabetes.The study included 76 patients with COPD III (40.8%) and COPD IV (59.2%) in combination with type 2 diabetes, 72 (94.7%) men and 4 (5.3%) women, averaga age 64.72 years. All patients were current or past smokers, the smoking index- 45.11. The duration of COPD was 8.71 years, the lasting of diabetes mellitus was 10.23 years. All patients were overweight, BMI=31.67 kg/m2. ±Before vaccination, patients reported severe clinical symptoms (CAT=27.99±3.79, CI 95% 19-36) and particularly severe dyspnea (mMRC=2.72±0.53, CI 95% 2-4), frequent exacerbations (3.45±0.85, CI 95% 2-5) episodes per year, in 33 (43.4%) with hospitalization and pneumonia in 17 (22.37%) patients.Three years after the PCV13 vaccination, the number of exacerbations of COPD significantly decreased by 1.47±0.71 (p<0.05, CI 95% 0-3) episodes per year, the number of hospitalizations decreased 5.5 times (6 patients needed) and pneumonia decreased 8.5 times (2 cases). A significant decrease in the number of exacerbations was accompanied by a decrease in the severity of clinical symptoms CAT=22.41±3.59, p<0.05 (CI 95% 14-32) including dyspnea reduction mMRC=2.24±0.43, p<0.05 (CI 95% 2-3). The reduction in the number of COPD exacerbations was also accompanied by an improvement of respiratory function - FEV1=38.83±9.86 vs 40.29±9.83, p<0.05.Thus, PCV13 vaccination of patients with COPD in combanation with diabetes mallitus can improve the course of the disease by reduction the number of exacerbations and decreasing the incidence of pneumonia.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4318.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -